Bayer Pharma Aktiengesellschaft

Bayer Healthcare LLC

Basf Agricultural Solutions Seed US LLC

Bayer Aktiengesellschaft

Bayer Intellectual Property Gmbh

Michael Strerath

Frank Dittmer

Jan Tebbe

Uwe Gritzan

Wayne Coco

Christoph Gerdes

Martina Schäfer

Anja Buchmüller

Andreas Wilmen

Erik Tucker

Joanna Grudzinska-Goebel

Ricarda Finnern

Philberta Y Leung

Asako Itakura

Terry Hermiston

Fabien Poree

Bernd Laber

Gudrun Lange

Ernst Weber

Manuel Dubald

Marc Linka

John E Murphy

Ye Jin

Nina Wobst

Hannah Jörißen

Nikolaus Pawlowski

Timothy Myles

Julia Straßburger

Christina Thies

Sandra Geske

Heike Balven-Ross

Christian Votsmeier

Ulrich Haupts

Susanne Steinig

Peter Scholz

Andreas Scheidig

Simone Brückner

Kornelia Kirchner

Kerstin Baral

Klaus Pellengahr

Hanna Plittersdorf

Christian Bender

Julia Straβburger

Julia Strassburger

Hannah Jöriβen

Simone Brueckner

Wayne M Coco

Julio Cesar Bolivar Lopez

Johanna Völker

Martina Schafer

Anja Buchmuller

Hannah Jorissen

Jan Tebe

The present invention relates to the identification of antibodies and/or antibody fragments in a selection process. The present invention relates to a method, a system and a computer program product for identifying pairs of genes which encode the variable domains of light and heavy chains of selected antibodies and/or antibody fragments.

Identifying the pairing of variable domains of light and heavy chains of antibodies

In the present invention, HPPD polypeptides and plants containing them showing a full tolerance against one or more HPPD inhibitor herbicides belonging to various chemical classes are described. A set of mutant HPPD polypeptides have been designed which have either no or only a significantly reduced affinity to HPPD inhibitor herbicides and, at the same time, the rate of dissociation of the HPPD inhibitors of the mutant HPPD polypeptide is increased to such an extent that the HPPD inhibitors no longer act as slow-binding or slow, tight-binding inhibitors but, instead of this, have become fully reversible inhibitors. In particular, isolated polynucleotides encoding mutant HPPD polypeptides conferring tolerance to HPPD inhibitor herbicides belonging to various chemical classes are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed.

HPPD variants and methods of use

The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.

Antibodies capable of binding to the coagulation factor XIa and uses thereof

This patent document relates to antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human antithrombin &#x3b2; complexed with heparin and/or heparin-like structure (AT&#x3b2;H). These AT&#x3b2;H binding proteins can block the anti-coagulant activity of AT&#x3b2; to induce coagulation. Therapeutic uses of these antibodies and binders are described herein as are methods of panning and screening specific antibodies.

Monoclonal antibodies against antithrombin beta

Nucleic acids and host cells expressing antibodies capable of binding to the coagulation factor XIa and uses thereof

Monoclonal antibodies against antithrombin &#x3b2;

Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof

Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNF&#x3b1;); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.

Antibodies to TNF&#x3b1;

Growing community of inventors

Düsseldorf, Germany

Michael Strerath